Fluralaner Dual-Pellet Implants for Rapid, Sustained Parasite Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing implant technologies for isoxazoline compounds in livestock do not provide a controlled release profile, leading to ineffective and inefficient parasite control, as they either lack sustained release mechanisms or result in rapid drug depletion.

Innovation Solution

A dual-pellet implant system comprising immediate and delayed release fluralaner pellets, where each pellet contains fluralaner and pharmaceutically acceptable excipients, with specific ratios and coatings to achieve sustained parasite control over an extended period.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If conventional implant formulations are used, then the implant structure is simple, but the release profile is uncontrolled and drug depletion occurs rapidly

Engineering Contradiction:

Improveduration of parasite controlVSAvoidimplant formulation complexity

Core Design Contradiction:

Duration of action of moving objectVSDevice complexity

Solution Approach 1:

The implant is divided into multiple pellets with different release characteristics (immediate release pellets and delayed release pellets). This segmentation allows the system to provide both rapid onset and prolonged duration of action, resolving the contradiction between simple structure and controlled release profile.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Different regions of the implant (different pellets) have different release properties. The immediate release pellets provide rapid drug release for quick parasite control, while delayed release pellets provide sustained release for long-term protection. This local differentiation of release characteristics achieves controlled release without requiring complex system-wide mechanisms.

Inventive Principle:

Principle #3Local quality

2Speed

If immediate release formulation is used, then rapid parasite control is achieved, but sustained release is insufficient

Engineering Contradiction:

Improveonset of parasite controlVSAvoidduration of therapeutic effect

Core Design Contradiction:

SpeedVSDuration of action of moving object

Solution Approach 1:

The implant combines immediate release pellets and delayed release pellets into a single dual-pellet system. This merging allows the system to achieve both rapid onset (from immediate release pellets) and prolonged duration (from delayed release pellets), simultaneously satisfying both speed and duration requirements.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The delayed release pellets are pre-configured to release drug after a specific lag period, providing sustained therapeutic effect after the immediate release component has acted. This preliminary arrangement of different release timing ensures both rapid and prolonged control without requiring complex active control mechanisms.

Inventive Principle:

Principle #10Preliminary action

3Duration of action of moving object

If delayed release formulation is used, then sustained parasite control is achieved, but rapid onset is insufficient

Engineering Contradiction:

Improveduration of therapeutic effectVSAvoidonset of parasite control

Core Design Contradiction:

Duration of action of moving objectVSSpeed

Solution Approach 1:

The dual-pellet system merges immediate release and delayed release components, allowing the immediate release pellets to provide rapid onset while the delayed release pellets ensure sustained duration. This combination resolves the contradiction by providing both speed and duration through integrated design.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

By segmenting the implant into two functional components with different release timing, the system can independently optimize for both rapid onset and prolonged duration. The segmentation allows each component to fulfill its specific function without compromising the other, achieving both speed and duration goals.

Inventive Principle:

Principle #1Segmentation

4Manufacturing precision

If single-pellet formulation is used, then the implant structure is simple, but controlled release profile cannot be achieved

Engineering Contradiction:

Improverelease profile controlVSAvoidimplant structure complexity

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The implant is segmented into multiple pellets with different release characteristics, allowing precise control over the release profile. This segmentation enables independent optimization of each pellet's release properties, achieving manufacturing precision in release control while maintaining relatively simple individual pellet structures.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Different pellets within the implant have different local qualities in terms of release characteristics. This local differentiation allows precise control over the overall release profile by adjusting the properties of individual pellets, achieving manufacturing precision without requiring complex system-wide control mechanisms.

Inventive Principle:

Principle #3Local quality

Data Source

PatentEP3723483B1Implantable fluralaner pharmaceutical compositions and uses thereof

Publication Date: 2025.09.03 INTERVET INT BV

Figure 1
Figure 2
Figure 3

AI summary

An implant for the control of parasites in livestock comprising an isoxazoline compound of Formula (I) or salt or solvate thereof, wherein the implant comprises one or more pellets each of which comprises the isoxaxoline compound and a pharmaceutically acceptable excipient and a method of preventing or treating a parasite infestation using the same.